AER-271 is under clinical development by Aeromics and currently in the Phase I in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect AER-271’s likelihood of approval (LoA) and phase transition for Cerebral Edema took place on 13 Dec 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their AER-271 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
AER-271 is under development for the treatment of stroke-related cerebral edema. It is administered through intravenous bolus and intravenous route. It is a prodrug of active free phenol derived phosphonic acid (AER-270). The drug candidate acts by targeting aquaporin-4 (AQP4), a water-channel protein.
Aeromics is a biopharmaceutical company that develops and markets drugs for the treatment of cerebral edema in stroke. The company is headquartered in New Haven, Connecticut, the US.
Quick View AER-271 LOA Data
|Highest Development Stage|